Bausch + Lomb's enVista Envy IOL Demonstrates Superior Visual Performance in Pivotal Clinical Trial
核心洞察
The enVista Envy (搜索) full range of vision intraocular lens met all primary efficacy and safety endpoints in a multicenter study of 501 cataract (搜索) patients.
The lens demonstrated statistical superiority for intermediate and near visual acuity compared to monofocal IOLs while maintaining non-inferiority for distance vision.
Results showed excellent visual performance with consistent acuity across multiple distances and a favorable safety profile with no treatment-emergent serious adverse events.
Bausch + Lomb Corporation (搜索) has announced the publication of pivotal U.S. clinical trial results for its enVista Envy (搜索) full range of vision intraocular lens (IOL) in the American Journal of Ophthalmology. The multicenter study demonstrated that the novel IOL met all primary efficacy and safety endpoints while delivering superior visual performance compared to traditional monofocal lenses in cataract (搜索) surgery patients.
Clinical Trial Design and Methodology
The prospective, masked, controlled trial randomized 501 cataract (搜索) patients into two groups across multiple centers. The study group (n=332) received bilateral implantation of the enVista Envy (搜索) IOL, while the control group (n=169) received the enVista monofocal IOL (搜索) (MX60E). Primary efficacy endpoints included monocular corrected distance visual acuity (CDVA, 4m), distance-corrected intermediate visual acuity (DCIVA, 66cm), and distance-corrected near visual acuity (DCNVA, 40cm).
Investigators also measured binocular visual acuity parameters including DCIVA, DCNVA, uncorrected intermediate visual acuity (UIVA), and uncorrected near visual acuity (UNVA) during the postoperative period from day 120-180. Primary safety endpoints encompassed adverse events, serious adverse events, and surgical interventions related to the IOL's optical properties throughout the same timeframe.
Superior Visual Outcomes Across All Distances
The study achieved all primary efficacy endpoints, with the enVista Envy (搜索) demonstrating non-inferiority for monocular CDVA and statistical superiority for both monocular DCIVA and DCNVA compared to the monofocal control group. The Envy group showed significantly better performance across all binocular visual acuity measures, including UIVA, DCIVA, UNVA, and DCNVA (all p<0.0001).
"Trial results mirror what I have seen in my practice," said Mitchell Shultz, medical director at Shultz-Chang Vision (搜索) in Northridge, CA, and the study's lead author. "I have long relied on the enVista platform, and I will continue to rely on Envy as an excellent option for cataract (搜索) patients seeking an IOL that can provide a full range of vision with minimal visual disturbances, as well as precision astigmatism correction."
Consistent Performance and Safety Profile
The enVista Envy (搜索) demonstrated consistent visual acuity of approximately 0.1 logMAR across the range from -1.50 to -2.50 D. Importantly, the difference in mesopic contrast sensitivity without glare between the two groups was less than the minimum detectable difference of 0.15 logCS, indicating comparable contrast sensitivity performance.
The study met all primary safety endpoints with no treatment-emergent serious adverse events related to the study lens, no secondary surgical interventions due to the lens's optical properties, and no cumulative or persistent adverse events. This favorable safety profile supports the lens's clinical viability for widespread use in cataract (搜索) surgery.
Advanced Optical Technology
The enVista Envy (搜索) incorporates ActivSync Optic intelligent energy distribution technology, which optimizes vision across various lighting conditions. According to Luc Bonnefoy, president of Surgical at Bausch + Lomb, "Results of this study confirm the advantages that this lens offers – continuous range of vision from distance to near with excellent dysphotopsia tolerance."
Clinical Indications and Considerations
The enVista Envy (搜索) hydrophobic acrylic IOL is indicated for primary implantation in adult patients for visual correction of aphakia (搜索) with preoperative corneal astigmatism (搜索) of 1.0 D or less following cataract (搜索) removal. The lens is designed to mitigate presbyopia (搜索) effects by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity to aspheric monofocal IOLs.
The toric version of the enVista Envy (搜索) allows surgeons to address astigmatic patients with enhanced precision, offering 0.50D increments and the ability to treat corneal astigmatism (搜索) under 1.0D. However, physicians should consider potential visual disturbances including halos, starbursts, glare, and reduced contrast sensitivity that may occur with multifocal IOLs, particularly in low-light conditions.